Apollomics Inc. Class A Ordinary Shares (APLM) is a publicly traded Healthcare sector company. As of May 21, 2026, APLM trades at $13.53 with a market cap of $32.94M and a P/E ratio of 0.00. APLM moved +0.00% today. Year to date, APLM is -34.60%; over the trailing twelve months it is +143.69%. Its 52-week range spans $3.66 to $42.12. Rallies surfaces APLM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Apollomics Cash Falls to $3.3M, Posts $8.5M Licensing Revenue as Vebreltinib Nears H1 2027 IND: Apollomics ended 2025 with $3.3M in cash, down from $9.8M in 2024, after raising $4.1M via PIPE and generating $8.5M in licensing revenue. Vebreltinib is approved in China for three indications, has dosed over 600 patients globally, and targets a Phase 2/3 IND submission for NSCLC combo by H1 2027.
| Metric | Value |
|---|---|
| Price | $13.53 |
| Market Cap | $32.94M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $42.12 |
| 52-Week Low | $3.66 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
APLM analyst coverage data. Average price target: $0.00.